<DOC>
	<DOCNO>NCT01148797</DOCNO>
	<brief_summary>A study design evaluate role treatment biological agent - Canakinumab pediatric ( age 4-20 ) Familial Mediterranean Fever ( FMF ) patient intolerant resistant colchicine treatment . The study hypothesis Canakinumab reduce attack frequency severity .</brief_summary>
	<brief_title>Evaluate Safety Efficacy Canakinumab Pediatric Patients With Colchicine Intolerant Colchicine Resistant Familial Mediterranean Fever ( FMF )</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Brucellosis</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female subject 4 20 year age active type 1 FMF disease ( accord TelHashomer Long criterion diagnosis FMF ) genetic confirmation diagnosis ( study genetic confirmation define either homozygous compound heterozygous ) . 2 . Subjects must type 1 disease characterize recurrent short episode inflammation serositis , average least 3 well document acute FMF attack previous 3 month confirm treat physician , last less week , minimum 14 day attack free interval attack . 3 . Subjects must receive adequate trial colchicine , define treatment least 12 mg/d ( base subject age ) least 3 month , inability tolerate colchicine due adverse effect dose control acute attack frequency le one attack per month . 4 . Subjects treat antiIL1 therapy must complete washout experience least 2 attack since ( e.g . Anakinra : 3 day washout ; Rilonacept : 4 week washout ) 5 . Subjects treat antiTNF drug must undergo appropriate washout . Prior randomization , use Etanercept must discontinue 4 week use Adalimumab Infliximab must discontinue 8 week full list washout period current treatment supply 6 . If subject female childbearing potential , must agree use adequate contraception ( adequate contraception include abstinence ) duration trial 3 month , must negative serum urine pregnancy test prior administration dose study medication . 7 . Subject 's parent legal guardian provide write informed consent prior screen study , subject old 18 year provide informed consent him/herself . 1 . Patients endorgan dysfunction due amyloidosis ( e.g . exist biopsy proven amyloidosis proteinuria &gt; 0.5 gram per day ) 2 . Subjects take oral IV steroid within 1 month prior baseline . Subjects take steroids reason FMF may enrol study base discussion investigator sponsor . 3 . Presence history inflammatory rheumatic disease 4 . The subject active noninfective GI disease ( e.g. , inflammatory bowel disease ) , chronic acute renal hepatic disorder , significant coagulation defect . 5 . The subject AST ( SGOT ) , ALT ( SGPT ) BUN &gt; 2 x ULN creatinine &gt; 1.5 mg/dL , laboratory abnormality consider examine physician clinically significant within 28 day Baseline visit . 6 . Positive PPD test ( accord local guidance ) latent active TB infection exclude via QuantiFERON ( TSpot radiographic image need ) via Chest xray . 7 . The subject positive human immunodeficiency virus ( HIV ) status current ( acute chronic ) hepatitis B C 8 . Subjects pregnant lactate 9 . Presence active chronic infection major episode infection require hospitalization treatment i.v . antibiotic within 30 day oral antibiotic within 14 day prior screen 10 . Malignancy , except successfully excise squamous basal cell carcinoma skin 11 . The subject receive investigational medication within 30 day first dose study medication schedule receive investigational drug , study medication describe protocol , course study . 12 . The subject receive live virus vaccine within 3 month prior baseline visit . 13 . Any concurrent medical condition would , investigator 's opinion , compromise subject 's ability tolerate study drug would make subject unable follow protocol . 14 . History of/or current psychiatric illness would interfere ability comply protocol requirement provide informed consent . 15 . Subject history alcohol drug abuse within past 6 month would interfere ability comply protocol requirement . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>FMF , Colchicine resistant</keyword>
	<keyword>Colchicine intolerant</keyword>
	<keyword>Flare rate</keyword>
	<keyword>Canakinumab</keyword>
</DOC>